How much do you agree with the following statements? *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
The activity presented balanced, evidence-based content free of commercial bias.	The activity presented balanced, evidence-based content free of commercial bias. - Strongly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Disagree	The activity presented balanced, evidence-based content free of commercial bias. - Slightly disagree	The activity presented balanced, evidence-based content free of commercial bias. - Neither	The activity presented balanced, evidence-based content free of commercial bias. - Slightly agree	The activity presented balanced, evidence-based content free of commercial bias. - Agree	The activity presented balanced, evidence-based content free of commercial bias. - Strongly agree
The presenter(s) used an effective teaching strategy.	The presenter(s) used an effective teaching strategy. - Strongly disagree	The presenter(s) used an effective teaching strategy. - Disagree	The presenter(s) used an effective teaching strategy. - Slightly disagree	The presenter(s) used an effective teaching strategy. - Neither	The presenter(s) used an effective teaching strategy. - Slightly agree	The presenter(s) used an effective teaching strategy. - Agree	The presenter(s) used an effective teaching strategy. - Strongly agree
The presentation slides / digital materials / resources and handouts were high quality.	The presentation slides / digital materials / resources and handouts were high quality. - Strongly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Disagree	The presentation slides / digital materials / resources and handouts were high quality. - Slightly disagree	The presentation slides / digital materials / resources and handouts were high quality. - Neither	The presentation slides / digital materials / resources and handouts were high quality. - Slightly agree	The presentation slides / digital materials / resources and handouts were high quality. - Agree	The presentation slides / digital materials / resources and handouts were high quality. - Strongly agree
The content was relevant to / useful for my professional practice.	The content was relevant to / useful for my professional practice. - Strongly disagree	The content was relevant to / useful for my professional practice. - Disagree	The content was relevant to / useful for my professional practice. - Slightly disagree	The content was relevant to / useful for my professional practice. - Neither	The content was relevant to / useful for my professional practice. - Slightly agree	The content was relevant to / useful for my professional practice. - Agree	The content was relevant to / useful for my professional practice. - Strongly agree
The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care.	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly disagree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Neither	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Slightly agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Agree	The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care. - Strongly agree
The overall quality of the educational activity was excellent.	The overall quality of the educational activity was excellent. - Strongly disagree	The overall quality of the educational activity was excellent. - Disagree	The overall quality of the educational activity was excellent. - Slightly disagree	The overall quality of the educational activity was excellent. - Neither	The overall quality of the educational activity was excellent. - Slightly agree	The overall quality of the educational activity was excellent. - Agree	The overall quality of the educational activity was excellent. - Strongly agree

The activity successfully achieved its learning objectives by enhancing my ability to: *

	Strongly disagree	Disagree	Slightly disagree	Neither	Slightly agree	Agree	Strongly agree
Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making.	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Strongly disagree	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Disagree	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Slightly disagree	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Neither	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Slightly agree	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Agree	Identify diagnostic criteria for Hypoactive Sexual Desire Disorder (HSDD) and demonstrate the ability to use validated tools like the Decreased Sexual Desire Screener to guide clinical decision-making. - Strongly agree
Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use.	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Strongly disagree	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Disagree	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Slightly disagree	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Neither	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Slightly agree	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Agree	Evaluate candidacy for testosterone therapy in women with HSDD by reviewing baseline labs (including total/free testosterone, sex hormone binding globule) and assessing informed consent for off-label use. - Strongly agree
Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects.	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Strongly disagree	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Disagree	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Slightly disagree	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Neither	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Slightly agree	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Agree	Explain the evidence, risks, and benefits of testosterone therapy in women and design a follow-up plan, including Food and Drug Administration-approved options and monitoring protocols for labs, efficacy, and side effects. - Strongly agree
Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making.	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Strongly disagree	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Disagree	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Slightly disagree	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Neither	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Slightly agree	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Agree	Discuss patient-centered approaches to managing HSDD, incorporating biopsychosocial elements, sexual health counseling, and shared decision-making. - Strongly agree
Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines.	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Strongly disagree	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Disagree	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Slightly disagree	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Neither	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Slightly agree	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Agree	Assess suitability for menopausal hormone therapy (MHT) in women with chronic disease, using a thorough history and risk stratification based on current guidelines. - Strongly agree
Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral).	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Strongly disagree	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Disagree	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Slightly disagree	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Neither	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Slightly agree	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Agree	Discuss the safety profile of MHT in the context of comorbidities, including cardiovascular risk, breast cancer risk, and the role of the timing hypothesis and the type of hormone used (e.g., transdermal vs oral). - Strongly agree
Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy.	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Strongly disagree	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Disagree	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Slightly disagree	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Neither	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Slightly agree	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Agree	Formulate an individualized MHT plan and follow-up protocol, selecting the appropriate estrogen route/dose and progestogen (if uterus is intact), while considering the symptom burden and risk profile. Review optimization and adjustments during therapy. - Strongly agree
Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Strongly disagree	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Disagree	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Slightly disagree	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Neither	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Slightly agree	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Agree	Recognize the clinical significance of untreated vasomotor symptoms, including the impact on sleep, quality of life, work productivity, and the association between persistent hot flashes and increased risks of cardiovascular disease, bone loss, and cognitive decline - Strongly agree

What do you anticipate changing or how will you apply what you learned in your professional practice? *

How will you apply what you learned when working with providers of other disciplines or members of your interprofessional healthcare team? *

What barriers, if any, do you see to implementing these changes? *

Please provide feedback on your experience navigating this website and completing the CE process. *

Based on your educational needs, what topics would you like to see addressed in future educational activities? *

Please discuss any additional concerns or comments about this program and indicate whether the program met your expectations. *

attestation checkbox *

I completed this educational activity independently and in its entirety.

Leave this field blank